目的:探讨微小RNA-296-5p、S期激酶相关蛋白2(S-phase kinase-associated protein 2,Skp2)、核糖体蛋白L6(ribosomal protein L6,RPL6)与前列腺癌病理特征的关系及对手术预后的影响。方法:选取2018年1月至2023年1月120例前列腺患者,均...目的:探讨微小RNA-296-5p、S期激酶相关蛋白2(S-phase kinase-associated protein 2,Skp2)、核糖体蛋白L6(ribosomal protein L6,RPL6)与前列腺癌病理特征的关系及对手术预后的影响。方法:选取2018年1月至2023年1月120例前列腺患者,均行腹腔镜前列腺癌术治疗,对比不同病理特征患者miR-296-5p、Skp2、RPL6 mRNA表达水平,分析各指标与病理特征的关系。根据术后1年是否生化复发分为复发组(n=21)与未复发组(n=97),比较2组临床资料、miR-296-5p、Skp2、RPL6mRNA表达水平,分析miR-296-5p、Skp2、RPL6对手术预后的影响及预测价值。结果:不同病理分期、Gleason评分、术前血清前列腺特异性抗原(prostate specific antigen,PSA)水平、淋巴结转移患者miR-296-5p、Skp2、RPL6 mRNA表达水平比较,差异有统计学意义(F=12.927、22.416、10.088、34.239、20.180、12.208,t=4.649、-5.770、-5.713、4.716、-5.647、-6.884,均P=0.000);miR-296-5p与Gleason评分、病理分期、术前血清前列腺特异性抗原(prostate specific antigen,PSA)水平、淋巴结转移呈负相关(r=-0.578、-0.539、-0.517、-0.556,均P<0.001),Skp2、RPL6 mRNA与Gleason评分、病理分期、术前血清PSA水平、淋巴结转移呈正相关(r=0.531、0.507、0.476、0.493、0.494、0.473、0.420、0.505,均P<0.001);复发组淋巴结转移、病理分期、切缘阳性率、Gleason评分、高于未复发组,术后辅助治疗率低于未复发组(P<0.05);复发组miR-296-5p表达水平低于未复发组,Skp2、RPL6mRNA表达水平高于未复发组(P<0.05);校正前,logistic回归分析,病理分期、Gleason评分、淋巴结转移、切缘阳性、术后辅助治疗、miR-296-5p、Skp2、RPL6 mRNA是前列腺癌患者术后生化复发的影响因素(P<0.05),校正后,miR-296-5p、Skp2、RPL6mRNA仍是前列腺癌患者术后生化复发的影响因素(P<0.05);miR-296-5p、Skp2、RPL6联合预测前列腺术后生化复发的AUC为0.902(95%CI=0.833~0.949),大于各指标单独预测(P<0.05)。结论:前列腺癌患者miR-296-5p、Skp2、RPL6表达水平与病理特征、术后复发密切相关,三者联合预测前列腺术后生化复发具有较高的参考价值。展开更多
The crystal structure of the title compound ethyl 3-（4-chlorophenyl）-3,4-dihydro-6- methyl-4-oxo-2-（pyrrolidin-1-yl）furo[2,3-d]pyrimidine-5-carboxylate （C20H20ClN3O4, Mr= 401.84） has been prepared and determined...The crystal structure of the title compound ethyl 3-（4-chlorophenyl）-3,4-dihydro-6- methyl-4-oxo-2-（pyrrolidin-1-yl）furo[2,3-d]pyrimidine-5-carboxylate （C20H20ClN3O4, Mr= 401.84） has been prepared and determined by single-crystal X-ray diffraction. The crystal is of monoclinic, space group P21/n with a = 20.6215（9）, b = 8.5311（4）, c = 21.6886（9） A^°, β = 91.607（1）°, V = 3814.0（3）A^°^3, Z = 8, Dc = 1.400 g/cm^3, F（000） = 1680, μ = 0.233 mm^-1, R = 0.0718 and wR = 0.1545 for 6717 observed reflections with I 〉 2σ（I）. X-ray diffraction analysis reveals two crystallographically independent molecules in the asymmetric unit.展开更多
In this paper, CoMFA method was applied to study the 3D QSAR on a series of 3 anilinomethylene 6 alkyl (aryl) 5,6 2H dihydropyran 2, 4 dione compounds, which were designed and synthesized referring to the natural toxi...In this paper, CoMFA method was applied to study the 3D QSAR on a series of 3 anilinomethylene 6 alkyl (aryl) 5,6 2H dihydropyran 2, 4 dione compounds, which were designed and synthesized referring to the natural toxic Alternaric acid structure. The results displayed the information on modification of primary molecules and further synthesis of new bioactive compounds.展开更多
The title compound ethyl 2-（6-（1,3-dioxo-4,5,6,7-tetrahydro-lH-isoindol-2（3H）- yl）-7-fluoro-3-oxo-2H-benzo[b][1,4]oxazin-4（3H）-yl） butanoate 3 was synthesized by the reaction of ethyl 2-（6-amino-7-fluoro-3-ox...The title compound ethyl 2-（6-（1,3-dioxo-4,5,6,7-tetrahydro-lH-isoindol-2（3H）- yl）-7-fluoro-3-oxo-2H-benzo[b][1,4]oxazin-4（3H）-yl） butanoate 3 was synthesized by the reaction of ethyl 2-（6-amino-7-fluoro-3-oxo-2H-benzo[b][1,4]oxazin-4（3H）-yl） butanoate with 4,5,6,7- tetraydrophthalic anhydride, and its structure was determined by X-ray single-crystal diffraction. The crystal belongs to the monoclinic system, space group P2 1/n with a = 9.3469（2）, b = 16.7715（5）, c = 13.7153（4） A, β= 104.9680（10）°, μ = 0.107 mm^-1, Mr = 430.42, V= 2077.08（10） ,A3, Z= 4, Dc = 1.376 g/cm3, F（000） = 904, T= 296（2） K, R = 0.0508 and wR = 0.1478.展开更多
文摘目的:探讨微小RNA-296-5p、S期激酶相关蛋白2(S-phase kinase-associated protein 2,Skp2)、核糖体蛋白L6(ribosomal protein L6,RPL6)与前列腺癌病理特征的关系及对手术预后的影响。方法:选取2018年1月至2023年1月120例前列腺患者,均行腹腔镜前列腺癌术治疗,对比不同病理特征患者miR-296-5p、Skp2、RPL6 mRNA表达水平,分析各指标与病理特征的关系。根据术后1年是否生化复发分为复发组(n=21)与未复发组(n=97),比较2组临床资料、miR-296-5p、Skp2、RPL6mRNA表达水平,分析miR-296-5p、Skp2、RPL6对手术预后的影响及预测价值。结果:不同病理分期、Gleason评分、术前血清前列腺特异性抗原(prostate specific antigen,PSA)水平、淋巴结转移患者miR-296-5p、Skp2、RPL6 mRNA表达水平比较,差异有统计学意义(F=12.927、22.416、10.088、34.239、20.180、12.208,t=4.649、-5.770、-5.713、4.716、-5.647、-6.884,均P=0.000);miR-296-5p与Gleason评分、病理分期、术前血清前列腺特异性抗原(prostate specific antigen,PSA)水平、淋巴结转移呈负相关(r=-0.578、-0.539、-0.517、-0.556,均P<0.001),Skp2、RPL6 mRNA与Gleason评分、病理分期、术前血清PSA水平、淋巴结转移呈正相关(r=0.531、0.507、0.476、0.493、0.494、0.473、0.420、0.505,均P<0.001);复发组淋巴结转移、病理分期、切缘阳性率、Gleason评分、高于未复发组,术后辅助治疗率低于未复发组(P<0.05);复发组miR-296-5p表达水平低于未复发组,Skp2、RPL6mRNA表达水平高于未复发组(P<0.05);校正前,logistic回归分析,病理分期、Gleason评分、淋巴结转移、切缘阳性、术后辅助治疗、miR-296-5p、Skp2、RPL6 mRNA是前列腺癌患者术后生化复发的影响因素(P<0.05),校正后,miR-296-5p、Skp2、RPL6mRNA仍是前列腺癌患者术后生化复发的影响因素(P<0.05);miR-296-5p、Skp2、RPL6联合预测前列腺术后生化复发的AUC为0.902(95%CI=0.833~0.949),大于各指标单独预测(P<0.05)。结论:前列腺癌患者miR-296-5p、Skp2、RPL6表达水平与病理特征、术后复发密切相关,三者联合预测前列腺术后生化复发具有较高的参考价值。
基金supported by the Natural Science Foundation of Hubei Province (2006ABB016)Key Science Research Project of Hubei Provincial Department of Education (No.D200724001) the Science Research Project of Yunyang Medical College (No. 2006QDJ16)
文摘The crystal structure of the title compound ethyl 3-（4-chlorophenyl）-3,4-dihydro-6- methyl-4-oxo-2-（pyrrolidin-1-yl）furo[2,3-d]pyrimidine-5-carboxylate （C20H20ClN3O4, Mr= 401.84） has been prepared and determined by single-crystal X-ray diffraction. The crystal is of monoclinic, space group P21/n with a = 20.6215（9）, b = 8.5311（4）, c = 21.6886（9） A^°, β = 91.607（1）°, V = 3814.0（3）A^°^3, Z = 8, Dc = 1.400 g/cm^3, F（000） = 1680, μ = 0.233 mm^-1, R = 0.0718 and wR = 0.1545 for 6717 observed reflections with I 〉 2σ（I）. X-ray diffraction analysis reveals two crystallographically independent molecules in the asymmetric unit.
文摘In this paper, CoMFA method was applied to study the 3D QSAR on a series of 3 anilinomethylene 6 alkyl (aryl) 5,6 2H dihydropyran 2, 4 dione compounds, which were designed and synthesized referring to the natural toxic Alternaric acid structure. The results displayed the information on modification of primary molecules and further synthesis of new bioactive compounds.
基金Supported by the National Natural Science Foundation of China (20872033, 20575019)Natural Science Foundation of Hunan Province (07JJ1003)+1 种基金Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research (Ministry of Education of China) (KLCBTCMR2008-14)Scientific Research Fund of Science and Technology Department of Hunan Province (No. 2006GK3067)
文摘The title compound ethyl 2-（6-（1,3-dioxo-4,5,6,7-tetrahydro-lH-isoindol-2（3H）- yl）-7-fluoro-3-oxo-2H-benzo[b][1,4]oxazin-4（3H）-yl） butanoate 3 was synthesized by the reaction of ethyl 2-（6-amino-7-fluoro-3-oxo-2H-benzo[b][1,4]oxazin-4（3H）-yl） butanoate with 4,5,6,7- tetraydrophthalic anhydride, and its structure was determined by X-ray single-crystal diffraction. The crystal belongs to the monoclinic system, space group P2 1/n with a = 9.3469（2）, b = 16.7715（5）, c = 13.7153（4） A, β= 104.9680（10）°, μ = 0.107 mm^-1, Mr = 430.42, V= 2077.08（10） ,A3, Z= 4, Dc = 1.376 g/cm3, F（000） = 904, T= 296（2） K, R = 0.0508 and wR = 0.1478.
